Shots:
- Lexicon has granted Novo Nordisk exclusive global rights to develop, manufacture & commercialize LX9851 (oral ACSL5 inhibitor) in all indications
- As per the deal, Lexicon will receive $45M upfront, ~$485M in regulatory & launch milestones, ~$475M in sales milestones, & tiered royalties from single to low-double-digit % of annual net sales. Lexicon will complete agreed upon IND-enabling activities, after which Novo will file for IND & lead further development
- In preclinical studies, LX9851 + semaglutide showed a reduction in weight, food intake & fat mass, plus mitigated weight regain & improved liver steatosis post-semaglutide discontinuation; data was presented at the Obesity Week 2024
Ref: Lexicon | Image: Lexicon & Novo Nordisk
Related News:- Viatris Join Forces with Lexicon Pharmaceuticals to Commercialize Sotagliflozin Across all Markets Outside of the US and EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
